Richard J. Rodgers
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Ardelyx shares IBSRELA real-world data at ACG 2026. Ardelyx presented new real-world data at the ACG 2026 Annual Meeting showing that starting IBSRELA reduced healthcare resource use for patients with IBS-C. The company highlighted significant drops in GI-related medical visits and tests following treatment initiation. This clinical update adds to the evidence base for the drug's value in managing chronic gastrointestinal conditions.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Opus Genetics to Present at Euretina 2026. Opus Genetics announced it will present data at the Euretina 2026 conference. This event is relevant as it provides a platform for the company to share scientific updates on its gene therapy programs. The stock currently trades below the average analyst target price, with a 52-week range spanning from $1.32 to $7.07.
Transaction History
| NVAX | ▲ Buy | Option Exercise | 18,880 | — | 6/20/2026 | View on chart |
| ARDX | ▲ Buy | Grant | 26,455 | $0 | 6/16/2026 | View on chart |
| IRD | ▲ Buy | Grant | 24,367 | $0 | 4/20/2026 | View on chart |
| NVAX | ▲ Buy | Option Exercise | 3,800 | — | 10/29/2025 | View on chart |
| ARDX | ▲ Buy | Grant | 41,551 | $0 | 6/18/2025 | View on chart |
| ARDX | ▲ Buy | Grant | 21,468 | $0 | 6/18/2025 | View on chart |
| NVAX | ▲ Buy | Option Exercise | 10,420 | $0 | 6/12/2025 | View on chart |
| IRD | ▲ Buy | Grant | 79,504 | $0 | 4/30/2025 | View on chart |
| ARDX | ▲ Buy | Option Exercise | 100,000 | $55K | 1/16/2025 | View on chart |
| NVAX | ▲ Buy | Option Exercise | 3,800 | $0 | 10/29/2024 | View on chart |
| ARDX | ▲ Buy | Grant | 12,204 | $0 | 6/14/2024 | View on chart |
| NVAX | ▲ Buy | Option Exercise | 6,670 | $0 | 6/12/2024 | View on chart |
| IRD | ▲ Buy | Grant | 41,143 | $0 | 6/11/2024 | View on chart |
| IRD | ▲ Buy | Grant | 24,762 | — | 1/1/2024 | View on chart |
| IRD | ▲ Buy | Grant | 35,000 | $0 | 11/1/2023 | View on chart |
| NVAX | ▲ Buy | Option Exercise | 3,800 | — | 10/29/2023 | View on chart |
| ARDX | ▲ Buy | Grant | 18,494 | $0 | 6/15/2023 | View on chart |
| IRD | ▲ Buy | Grant | 50,000 | $0 | 4/19/2023 | View on chart |
| IRD | ▲ Buy | Grant | 20,822 | — | 1/11/2023 | View on chart |
| IRD | ▼ Sell | Other | 3,148 | $0 | 10/3/2022 | View on chart |
| IRD | ▲ Buy | Grant | 7,812 | — | 7/1/2022 | View on chart |
| IRD | ▲ Buy | Grant | 15,841 | — | 7/1/2022 | View on chart |
| ARDX | ▲ Buy | Grant | 132,299 | $0 | 6/15/2022 | View on chart |
| IRD | ▲ Buy | Grant | 4,629 | — | 4/1/2022 | View on chart |
| IRD | ▲ Buy | Grant | 4,021 | — | 1/3/2022 | View on chart |
| IRD | ▲ Buy | Grant | 2,912 | — | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
NVAX Rallies 16% on NIH Cancer Vaccine Push Reports
Novavax shares surged 16% as part of a broader rally in vaccine stocks, driven by reports that the NIH is planning a major push for cancer vaccines. This news lifted the entire sector, with peers like Moderna and Merck also seeing significant gains. The move pushed NVAX into overbought territory, with its RSI reaching 68.6, though it remains below the average analyst target price.
NVAX Rallies 16% on NIH Cancer Vaccine Push Reports. Novavax shares surged 16% as part of a broader rally in vaccine stocks, driven by reports that the NIH is planning a major push for cancer vaccines. This news lifted the entire sector, with peers like Moderna and Merck also seeing significant gains. The move pushed NVAX into overbought territory, with its RSI reaching 68.6, though it remains below the average analyst target price.